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Abstract Infections caused by community-acquired meth-
icillin-resistant Staphylococcus aureus (MRSA) are emerg-
ing as a major public health problem. In this study, we
describe the distribution of 54 Panton-Valentine leucocidin
(PVL)-carrying MRSA isolates in the northern Netherlands
between 1998 and 2005, of which 43 (80%) consisted of
the European PVL-positive strain multi locus sequence type
80 with staphylococcal cassette chromosome mec type IVc
(ST80). Individual cases and small clusters of ST80
predominated in the community (74%), but ST80 was also
found in nursing homes (16%) and hospitals (9%). Long-
term carriership (months to years) and reinfection of
patients with ST80 has probably led to the strain spreading
in the community and subsequently to further migration to
health care environments.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is an
important cause of hospital-acquired infections and a
serious public health concern [1]. In European hospitals,
high prevalences of MRSA (>40%) are reported in Greece,
Ireland, UK, Italy and Malta, and low prevalences (<1%) in
the Netherlands, Denmark, Sweden, Finland, Iceland and
Estonia [2]. The low prevalence in Dutch hospitals can be
explained by restrictive antibiotic use and our national
“search-and-destroy” policy [3], which requires that
patients who are repatriated from foreign countries, contacts
of MRSA patients, citizens and patients from abroad are
strictly isolated at hospital admission until screening
cultures for MRSA prove negative. In case of MRSA
carriership or infection, patients are kept in isolation and
receive eradication therapy. The low prevalence of MRSA
in hospital settings may be endangered by an increasing
number of outbreaks of community-acquired MRSA (CA-
MRSA) [4], resulting in migration of these strains to health
care environments.
CA-MRSA infections mainly cause primary skin and
soft tissue infections (SSTI) [5] or necrotising pneumonia in
previously healthy patients. The majority of CA-MRSA
strains harbour the Panton-Valentine leukocidin (PVL)
genes, which encode for a bicomponent hymenotropic
toxin responsible for pore formation in leucocytes, whereas
most hospital MRSA strains do not. Other virulence factors
associated with CA-MRSA are the superantigen staphylo-
coccal enterotoxins (SE) B, C and H [1].
In the Netherlands, the prevalence of PVL-positive
MRSA has increased over the last 5 years, and in 2004
the proportion of all MRSA isolates in the Netherlands that
was PVL positive was 10% [6]. We surveyed all PVL-
positive MRSA isolates collected in our laboratories over a
period of 6 years and 8 months to describe the spread of the
PVL-positive MRSA strain staphylococcal cassette chro-
mosome mec type IVc (ST80) between 1998 and 2005,
using molecular typing and retrospective review of avail-
able medical records.
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Materials and methods
We studied all PVL-positive MRSA isolates cultured
between August 1998 and March 2005 in the northern
Netherlands. The study area consisted of the Dutch
provinces Groningen and Drenthe (5,639 km2; 1,058,407
inhabitants). All MRSA isolates were cultured at the
Laboratory for Infectious Diseases in Groningen (37
isolates) and the laboratory of the Department of Medical
Microbiology of the University Medical Centre, Groningen
(17 isolates), which cover all general practitioners, nursing
homes, outpatient clinics and hospitals of the region.
Isolates were obtained from cultures of patients displaying
typical staphylococcal disease syndromes (e.g. SSTI) or
during routine MRSA screening as part of our national
search-and-destroy policy (cultures of nose, throat and
perineum). From each patient, only one PVL-positive
MRSA isolate was included in the study. Clinical informa-
tion regarding MRSA patients was obtained from their
primary physicians by standardised questions.
Infections were classified as community acquired if
isolates were obtained outside a hospital or nursing home
setting or less than 48 h after hospital admission. In case of
an MRSA infection involving personnel of a health care
facility, acquisition was classified as community acquired
when no previous contact with an MRSA-positive patient
could be established. Foreign travel, hospitalisation or
residence in a nursing home during the year before
infection, outpatient visits and work in a care facility were
considered risk factors for MRSA acquisition.
Patients positive for CA-MRSA underwent decolonisa-
tion therapy with mupirocin and Hibiscrub. Household
contacts were screened for MRSA and received decoloni-
sation therapy when they tested positive. After 3 weeks, the
nose, throat and perineum were recultured for MRSA
screening. Repetitive cultures were obtained according to
the Working Group Infection Prevention (WIP) guidelines
for MRSA [7]. Decolonisation therapy was continued if
these cultures were MRSA positive and terminated if
cultures were MRSA negative. In case of long-term
carriership, patients were screened for MRSA with 3- to
6-week intervals and continued to receive decolonisation
therapy until proven culture negative.
Colonies characteristic for Staphylococcus aureus were
identified by DNase and tube coagulase tests. Susceptibility
was tested by the disc diffusion method, as recommended
by the Clinical and Laboratory Standards Institute (CLSI)
[8], against oxacillin (Oxoid B.V. Haarlem, the Netherlands),
kanamycin, gentamicin, trimethoprim, trimethoprim-sulfa-
methoxazole, erythromycin, tetracycline, clindamycin, cipro-
floxacin, rifampicin, vancomycin, mupirocin and fusidic acid
(NeoSensitabs, Rosco, Taastrup, Denmark). Isolates were
also screened for minimum inhibitory concentration (MIC)
of tetracycline, minocycline and fusidic acid by E-test and
for inducible resistance to minocycline by tetracycline by
double-disc diffusion [9]. Methicillin resistance was con-
firmed by the penicillin binding protein (PBP) 2′ latex
agglutination test (Denka Seiken, Tokyo, Japan). Addition-
ally, the mecA gene was identified using the Genotype
MRSA test (Hain Lifescience GmbH, Nehren, Germany).
DNA was extracted after prelysis with lysostaphin, as
described previously [10]. Sequences specific for SEs A, B,
C, D and E; exotoxin A (ETA); and toxic shock syndrome
toxin 1 (TSST-1) were detected by polymerase chain
reaction (PCR) using primers described previously [11].
Primer sequences used to amplify a 186 bp section of the
SE-H gene were forward 5′ GCAGTTGCAAACTT-
TACTCTCAAA 3′, reverse: 5′ CGAAAGCAGAAGATT-
TACACGATA 3′. Primer sequences used to amplify a
530 bp section of the PVL gene lukS-PV were forward 5′
ATGACTCAGTAAACGTTGTAGAT 3′, reverse 5′
TCTATCCATTTCACTTTGATAAGT 3′. Primer sequences
used to amplify a 305 bp section of tetracycline resistance
determinant tet K were forward 5′ ATGTGCTATTCCCCC-
TATTGA 3′, reverse 5′ TCGATAGGAACAGCAGTA-
TATGGA 3′. Primers for amplification of a 385 bp
section of the Nuc gene (specific for S. aureus) were added
as a control in all PCR runs: forward 5′ CGCTAC-
TAGTTGCTTAGTGTT 3′, reverse 5′ CACGTCCAT ATT-
TATCAGTTC 3′. All primers were developed using
Primer3. PCR products were resolved by electrophoresis
with 1% agarose gels, which were stained with ethidium
bromide and analysed. SCCmec typing was initially
performed by Ito on two isolates and resulted in SCCmec
type IVc, after which all isolates were tested for SCCmec
type IVc [12].
MRSA isolates were genotyped by pulsed-field gel
electrophoresis (PFGE) after SmaI macrorestriction, and
PFGE patterns were interpreted according to criteria
proposed by Tenover et al. [13]. PVL-positive MRSA
isolates in the follow-up cultures were not subjected to
PFGE analysis. These isolates were considered identical if
the PBP2′ latex agglutination test was positive and resistance
patterns were similar. Furthermore, all MRSA isolates were
sent to the National Institute of Public Health and Environ-
ment (RIVM; Bilthoven, the Netherlands)—which serves as
the national reference centre for surveillance of MRSA in the
Netherlands—for verification of possession of mecA and
PVL genes and for additional typing.
Results and discussion
From August 1998 to March 2005, 54 PVL-positive MRSA
isolates were cultured in our laboratories. A total of 22% of
all MRSA isolates in the northern Netherlands were PVL
724 Eur J Clin Microbiol Infect Dis (2007) 26:723–727
positive, being twice as high as the Dutch national average
of 10% in the same time period [6]. Multilocus sequence
typing (MLST) characterised ST80 as the predominant
PVL-positive MRSA strain in the Netherlands, covering
20% of all PVL-positive MRSA isolates [6]. In the northern
Netherlands, 43 of the 54 PVL-positive MRSA isolates
(80%) were characterised as PFGE cluster 28 (RIVM),
previously identified by MLST as the ST80 strain [6]. Data
were collected using the same sample frame and compara-
ble methodology.
The first appearance of the ST80 strain in the northern
Netherlands was in 1998, and since 2002, the ST80 strain
was identified repeatedly in the northern Netherlands.
Individual infections and small clusters (involving two to
five patients) of infection or colonisation with ST80
occurred 29 times, without apparent patient contacts
between these individual cases or clusters. Patients of all
ages harboured the ST80 strain (median age 48 years; range
0–91). Apart from the ST80 strain, seven different PVL-
positive strains as determined by PFGE (not shown) were
cultured from 11 patients. Identical strains in this “non-
ST80” group were found only within families.
All ST80 isolates contained genes for mecA, tetK, PVL
and SEH. SCCmec type IVc was confirmed in 42 of the 43
isolates (98%). All ST80 strains were susceptible to
gentamicin, trimethoprim, trimethoprim-sulfamethoxazole,
erythromycin, clindamycin, ciprofloxacin, rifampicin, van-
comycin and mupirocin. Apart from resistance to beta-
lactam antibiotics and kanamycin, all ST80 isolates showed
resistance to fusidic acid (MIC range 8–16 μg/ml) and
tetracycline (MIC range 16–24 μg/ml). Since all isolates
were susceptible to minocycline (MIC range ≤0.125 μg/ml)
without induction of resistance by tetracycline, resistance to
tetracycline was determined only by tetK, without interfer-
ence of tetM. Acquisition of fusidic acid and tetracycline
resistance by ST80 strains in the community may be due
to the frequent subscription of fusidic acid or tetracycline
by general practitioners to patients with SSTI [14]. In
other European studies regarding the ST80 strain, tetracy-
cline- and fusidic-acid-resistant and susceptible strains
were described, as well as additional resistance to
ciprofloxacin, erythromycin or chloramphenicol and dif-
ferences in the presence of toxins [1]. Although the ST80
strain is considered to be a single European strain,
mutations and different antibiotic regimens between
countries may increasingly lead to the development of
heterogeneous strains.
Table 1 shows the assumed location of acquisition of the
PVL-positive MRSA isolates. The majority of ST80
isolates (32 of 43, 74%) was acquired in the community,
of which 16 (37%) were isolated from patients without risk
factors for MRSA acquisition. Nine ST80 isolates (21%)
were recovered from community patients with risk factors
for MRSA acquisition, consisting of hospitalisation or
outpatient visits in the year before infection. However, as
no MRSA infections were registered in the hospital wards
or outpatient clinics during admittance or visits of any of
these patients, acquisition of the ST80 strain may still have
been truly community acquired. Nevertheless, prior health
care exposure could have predisposed these patients to
become colonised with a community-dwelling MRSA
strain due to antibiotic use or chronic illness [15]. Seven
ST80 isolates (16%) were derived from household contacts
(predominantly colonisation), five originating from true
Table 1 Location of acquisition and initial source of isolation of all 54 Panton-Valentine leucocidin (PVL)-positive methicillin-resistant
Staphylococcus aureus isolates [staphylococcal cassette chromosome mec type IVc (ST80) and non-ST80] cultured between 1998 and 2005 in the
northern Netherlands
Location of acquisition Number (%) Source of isolation
SSTI Colonisation Other
ST80 (n=43) Community
no risk factors 16 (37) 13 1 2
risk factors 9 (21) 6 2 1
household 7 (16) 3 2 2
Nursing home 7 (16) 6 1 –
Hospital 4 (9) – 3 1
Non-ST80 (n=11) Community
no risk factors 2 (18) 2 – –
risk factors 4 (36) 2 1 1
household 4 (36) – 4 –
Nursing home 1 (9) 1 – –
SSTI skin and soft tissue infections.
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CA-MRSA strains and two from family members of a
nursing home nurse, all three of them suffering furunculosis
by ST80. As only one nursing home patient in this small
outbreak was infected by ST80, it remained unknown
which individual was infected first and served as the index
patient. Four ST80 isolates (9%) were acquired in a
hospital. However, three of these hospital isolates could
be directly linked to the transfer of a nursing home patient
suffering a severe wound infection by ST80 to the hospital,
colonising two patients and a hospital nurse. Although
seven (16%) isolates were defined to be acquired in a
nursing home, in total, 28% of all ST80 isolates had a link
to a nursing home, making nursing homes a potential
intermediate for transmission of MRSA from the commu-
nity to the hospital. The majority (91%) of PVL-positive
non-ST80 isolates was also community acquired (Table 1),
although six strains (55%) involved adoption of children
from China, where the incidence of MRSA is high [1].
Most ST80 isolates, 28 of 43 (65%), were initially
isolated from various SSTI, predominantly wound infec-
tions, abscesses and furunculosis (Table 1). Nine patients
(21%) displayed no symptoms but MRSA screening
revealed colonisation with ST80 after contact with
MRSA-positive patients, most often household members.
ST80 was also obtained from cultures of several other
infections, including pneumonia, otitis media, conjunctivitis
(in two neonates) and sepsis, the latter resulting in the death
of one patient within 24 h after hospitalisation. The 11
PVL-positive non-ST80 isolates originated equally from
SSTI (five strains, 45%) or colonisation (45%), whereas
one was isolated from a patient with pneumonia.
Despite eradication therapy with a combination of
mupirocin, Hibiscrub and oral antibiotics (trimethoprim-
sulfamethoxazole, macrolides or clindamycin) in case of
invasive infection, a number of patients were found to be
carrying MRSA ST80 on follow-up screening cultures.
Control MRSA screening revealed that in 22 patients
(51%), one eradication treatment was successful within a
month. Several patients were shown to continue carrying
the MRSA strain for 2–3 months (seven patients, 16%),
6 months (four patients, 9%) or for over a year (ten patients,
23%). In one family, ST80 carriership for more than
2 years was demonstrated by 3- to 6-monthly MRSA
screening of a young infant and her mother, the latter
suffering serious SSTI by ST80 2 years after initial
colonisation. The ST80 carriership in this family led to
ST80 colonisation of the second child at birth and SSTI
by ST80 in another adult relative of this family, without
existing household membership.
The high occurrence of ST80 in the northern Nether-
lands can probably be ascribed to local spread of the ST80
strain in the community, where most strains were acquired.
Because there is no national policy for general practitioners
for handling a CA-MRSA infection, adequate MRSA
screening of all contacts (except screening of household
contacts) was not performed. Undetected carriership of
MRSA of individuals in close proximity may have led to
transmission and reinfection with MRSA by skin-to-skin
contact and contact with contaminated objects [1]. Not all
household contacts received eradication therapy simulta-
neously, which could also have contributed to reinfection of
the index patient. Furthermore, eradication therapy was not
always successful, as shown by prolonged carriership for
months to years. The combination of long-term carriership
and reinfection of index patients by individuals in their
close proximity has probably contributed to the local spread
of ST80 infections in relatively small areas and time span.
In conclusion, in the northern Netherlands, the high
occurrence of PVL-positive MRSA infection and coloni-
sation between 1998 and 2005 is mainly attributed to the
ST80 strain. Ongoing transmission of ST80 in specific
areas of the community may be explained by carriership
of individuals passing colonisation and infection back and
forth. Increasing occurrence of PVL-positive MRSA
strains in the community will ultimately lead to migration
of these strains to nursing homes and hospitals. Nursing
homes may increasingly serve as a potential source of
MRSA and an important risk factor for transmission to
hospitals. Early MRSA detection, proper screening of
patient contacts and adequate eradication therapy may in
time help to contain further spread of PVL-positive
MRSA strains in the community and, eventually, to health
care environments.
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